All News

Like other HCPs, pharmacists use AI-driven tools to support the delivery of pharmacy-related services.

Pharmacist-driven discharge medication reconciliation services identifies clinical interventions and may contribute to a decreased 30-day readmission rate.

A cardio-kidney-metabolic syndrome (CKM) guideline writing committee member outlines steps pharmacists can take to keep the kidney piece of CKM from being overlooked.

Andrew Li, PharmD, BCOP, discusses key targeted therapy updates in the 2026 ASCO living guideline for stage IV non–small cell lung cancer and how pharmacists can help manage treatment-related toxicities and access barriers.

Boston University researchers say flat chronic kidney disease (CKD) prevalence conceals a growing diabetes-linked burden, and pharmacists have a key role in closing screening gaps.

Beckley Retreats CEO Neil Markey discusses how the recent Executive Order on psychedelic therapies for veterans could reshape access to ibogaine and other investigational treatments.

New real-world data suggest pharmacists may have an expanding role in prioritizing GLP-1 therapy for patients managing both conditions.

Physicians oversee prescription medications the patient is taking, but OTC products bypass this system, and patients are often unaware of what can and cannot be taken.

This week's episode covers a multistate rise in cyclosporiasis infections, insights from a Yale psychiatrist on safety monitoring for psychedelic therapies, and a wave of FDA approvals spanning nephrology, gene therapy, and cell therapy—plus a major expansion of the NIH's All of Us Research Program.

Utah's AI-powered prescription refill pilot is fueling debate over how artificial intelligence can improve medication access and workflow efficiency while preserving the clinical oversight needed to ensure patient safety.

A study finds low-income and minority families are likely among those experiencing consequences from reduced measles, mumps, rubella, and varicella (MMRV) vaccine uptake amid the worst surge in US measles cases in decades.

The regimens are pembrolizumab plus enfortumab vedotin-ejfv (EV) and pembrolizumab with berahyaluronidase alfa-pmph and EV.

The FDA approval gives patients with multiple myeloma a second subcutaneous anti-CD38 option alongside daratumumab.

Pharmacy Times interviews Nicole McMullin, regional clinical pharmacist at American Oncology Network, on patient and caregiver education, home monitoring, multidisciplinary coordination, and key lessons for community oncology practices implementing outpatient BiTE therapy.

The FDA expanded Wilate's approval for routine prophylaxis to reduce bleeding episodes in children aged younger than 6 years with von Willebrand disease, supported by phase 3 WIL-33 data showing low annualized bleeding rates and favorable tolerability.

A study published in JAMA Network Open of opioid-naive patients with acute pain found that opioids were typically used in low doses and for short periods, but pain often lasted longer than expected, and leftover medication was common.

The tool can estimate recurrence risk across multiple subtypes, including those for which no guideline-recommended genomic prognostic tests currently exist.

Ennumo is approved for the same indications as its reference product, Neulasta (pegfilgrastim).

The new program gives eligible Medicare Part D beneficiaries access to Wegovy, Zepbound, and Foundayo for weight management at a flat $50 co-pay, but early claim-routing errors show pharmacists have a critical role in getting patients across the bridge.

These recommendations for acute pulmonary embolism management are most applicable to pharmacists on the interdisciplinary team managing acute PE.

In an interview with Pharmacy Times, Deanna Horner, PharmD, BCPS, discusses how pharmacists can serve as patient advocates in GLP-1 care and how direct access models may simplify the patient journey while preserving clinical oversight.

Tanya J. Uritsky, PharmD, BCPP, FPPCP, FASHP, discusses multimodal analgesia, acute pain pathways, opioid-tolerant patients, suzetrigine, and pharmacist-led interventions across health systems with Pharmacy Times.

A preclinical study demonstrates protective immunity against flu, COVID-19, and RSV without immune interference.

New findings show chronic kidney disease affects the same share of US adults as in 2013, although the disease is increasingly tied to diabetes and heart conditions.

Study authors suggest diabetic guidelines should consider standardized reporting of CGM metrics in studies employing CGM-based interventions.

Advances in antibiotic and microbiome-based therapies may reduce recurrence and improve outcomes in patients with recurrent Clostridioides difficile infection. 

Researchers found that excess abdominal fat suppresses immune surveillance in the lungs by increasing regulatory T cells, challenging the "obesity paradox."

The authors said these data support the safety of current coadministration practice.